Gosset Ownership
Private
Employees
~9
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Xias Bio General Information
Xias Bio has developed a proprietary molecular platform—LiteProtein™—to create animal-free multifunctional proteins with enhanced performance. These are being adopted by cosmetics and personal care companies as sustainable alternatives to animal-derived or single-function recombinant proteins. The company has secured early sales and strong industry interest. No clinical trial results reported; focus currently on industrial/commercial use.
Contact Information
Website
Primary Industry
Non-Drug Biotech
Corporate Office
Glasgow, Scotland
United Kingdom
United Kingdom
Drug Pipeline
No pipeline data available
Key Partnerships
Early commercial partnerships with cosmetic ingredient manufacturers and brands integrating LiteProteins into their portfolios.
Xias Bio Funding
No funding data available
To view Xias Bio's complete valuation and funding history, request access »